Remepy
Biotechnology · Health Care
Lately:5 news stories in 90 daysFollow changes →
Facts
as of Nov 17, 2026Redefining combination therapy by fusing traditional pharmaceuticals with clinically validated app-delivered protocols in a single, regulated prescription.
- Employees
- 11-50estimated range
- Website
- remepy.com
These are the key facts about Remepy on Alion as of Nov 17, 2026. The latest round is Series A of $36M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Financials
Funding rounds, investors and revenue on record.
$36MTotal raised
Series ALatest round
1Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
2026
$36M
Sources: funding announcements, grant and company registers
Milestones
Sep 16
Aug 12
Raised a round Series A $36M
Apr 28
Jan 2023
Website went live first capture in the Wayback Machine
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 292026
News · neurology live
Hybridopa improved MDS-UPDRS scores in a small phase 2a Parkinson disease trial, with phase 3 testing planned for 2026.
Sep 162026
Press release · PRNewswire
/PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the appointment of Eran Harary, MD, as Chief Medical Officer, effective October 1, 2026....
Sep 162026
News · thepharmaletter.com
Aug 202026
News · Pulse 2.0
Remepy has raised $36 million in Series A financing to advance its pipeline of Hybrid Drugs, including global Phase III development of Hybridopa for Parkinson's disease, bringing…
Aug 192026
News · parkinsonsnewstoday.com
Aug 132026
News · Tech Lens Media
Remepy raised $36M to advance Hybridopa into Phase III and expand its Hybrid Drug platform combining medicines with personalized AI-driven digital protocols.
Sources: the outlets named on each headline, each story once
